Harvoni (ledipasvir, sofosbuvir; Gilead) has been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG) to treat adults infected with chronic hepatitis C virus genotypes 1 and 4. It is approved as a 12-week course for patients without cirrhosis or compensated cirrhosis. See the AWMSG website for full details of restrictions.
Citation: The Pharmaceutical Journal URI: 20069157
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com